AVITA Medical’s New Collagen-Based Dermal Matrix: Cohealyx™
Valencia, CA – April 3, 2025 – AVITA Medical, Inc., a pioneering company in the field of therapeutic acute wound care, announced the commercial launch of Cohealyx™ in the United States. This innovative product, co-developed with Regenity Biosciences, is a collagen-based dermal matrix that promises to deliver transformative solutions for wound care.
What is Cohealyx™?
Cohealyx™ is a collagen-based dermal matrix designed to promote the natural healing process in acute wounds. It is derived from bovine collagen and includes a unique combination of glycosaminoglycans, elastin, and proteoglycans. These natural components work together to create a biocompatible scaffold that supports the growth of new tissue and accelerates the wound healing process.
How Does Cohealyx™ Work?
The collagen in Cohealyx™ acts as a template for the formation of new tissue in the wound. It provides structural support, allowing the wound to heal more efficiently. The glycosaminoglycans, elastin, and proteoglycans in the matrix help to maintain moisture and promote the production of new cells, further enhancing the wound healing process.
Impact on Individuals
For individuals with acute wounds, this new innovation can significantly reduce the time it takes for a wound to heal. Cohealyx™ can be used in a variety of wound types, including surgical incisions, traumatic injuries, and diabetic ulcers. By accelerating the healing process, patients can experience less pain, reduced scarring, and a quicker return to their normal daily activities.
- Faster wound healing
- Reduced pain
- Minimized scarring
- Quicker return to normal activities
Impact on the World
The global market for advanced wound care is projected to grow significantly in the coming years. With the commercial launch of Cohealyx™, AVITA Medical is poised to capture a larger share of this market. The innovation is expected to have a positive impact on healthcare systems worldwide by reducing the length of hospital stays, decreasing the need for costly wound care treatments, and improving patient outcomes.
- Growing market for advanced wound care
- Reduced hospital stays
- Decreased need for costly treatments
- Improved patient outcomes
Conclusion
The commercial launch of Cohealyx™ by AVITA Medical marks an exciting step forward in the field of therapeutic acute wound care. The collagen-based dermal matrix, co-developed with Regenity Biosciences, offers individuals with acute wounds the potential for faster healing, reduced pain, minimized scarring, and a quicker return to normal activities. Furthermore, the innovation is expected to have a significant impact on healthcare systems worldwide by reducing costs, improving patient outcomes, and contributing to the growing market for advanced wound care.
As we continue to push the boundaries of medical innovation, the possibilities for transformative solutions in the field of wound care are endless. AVITA Medical’s Cohealyx™ is a prime example of this progress and a promising development for individuals and healthcare systems alike.
